mavrilimumab
KPL-301-C001
Phase 2 other completed
Quick answer
mavrilimumab for Giant Cell Arteritis is a Phase 2 program (other) at Kiniksa Pharmaceuticals International, plc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Kiniksa Pharmaceuticals International, plc
- Indication
- Giant Cell Arteritis
- Phase
- Phase 2
- Modality
- other
- Status
- completed